Cargando…

Inactivation of RB1 , CDKN2A , and TP53 have distinct effects on genomic stability at side‐by‐side comparison in karyotypically normal cells

Chromosomal instability is a common feature in malignant tumors. Previous studies have indicated that inactivation of the classical tumor suppressor genes RB1, CDKN2A, and TP53 may contribute to chromosomal aberrations in cancer by disrupting different aspects of the cell cycle and DNA damage checkp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Andersson, Natalie, Saba, Karim H., Magnusson, Linda, Nilsson, Jenny, Karlsson, Jenny, Nord, Karolin H., Gisselsson, David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley & Sons, Inc. 2022
Materias:	Brief Reports
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10091693/ https://www.ncbi.nlm.nih.gov/pubmed/36124964 http://dx.doi.org/10.1002/gcc.23096

Ejemplares similares

Growth suppression by MYC inhibition in small cell lung cancer cells with TP53 and RB1 inactivation
por: Fiorentino, Francesco Paolo, et al.
Publicado: (2016)

Mutation analysis of genes that control the G1/S cell cycle in melanoma: TP53, CDKN1A, CDKN2A, and CDKN2B
por: Soto, José Luis, et al.
Publicado: (2005)

Glioblastomas with primitive neuronal component harbor a distinct methylation and copy-number profile with inactivation of TP53, PTEN, and RB1
por: Suwala, Abigail K., et al.
Publicado: (2021)

A Pan-Cancer Assessment of RB1/TP53 Co-Mutations
por: Cai, Ling, et al.
Publicado: (2022)

Detection and Correlation of Single and Concomitant TP53, PTEN, and CDKN2A Alterations in Gliomas
por: Pessôa, Igor Andrade, et al.
Publicado: (2019)

TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
por: Haase, Detlef, et al.
Publicado: (2019)

Study of polymorphisms in the TP53 and RB1 genes in children with retinoblastoma in northern Mexico
por: Anaya-Pava, Edwin J., et al.
Publicado: (2017)

Prevalence of TP-53/Rb-1 Co-Mutation in Large Cell Neuroendocrine Carcinoma
por: Saghaeiannejad Esfahani, Hoda, et al.
Publicado: (2021)

NSAIDs Modulate CDKN2A, TP53, and DNA Content Risk for Progression to Esophageal Adenocarcinoma
por: Galipeau, Patricia C, et al.
Publicado: (2007)

Female genital mutilation of a karyotypic male presenting as a female with delayed puberty
por: Ellaithi, M, et al.
Publicado: (2006)

miR-106b regulates the proliferation and differentiation of neural stem/progenitor cells through Tp53inp1-Tp53-Cdkn1a axis
por: Xia, Xiaohuan, et al.
Publicado: (2019)

CDKN2C-Null Leiomyosarcoma: A Novel, Genomically Distinct Class of TP53/RB1–Wild-Type Tumor With Frequent CIC Genomic Alterations and 1p/19q-Codeletion
por: Williams, Erik A., et al.
Publicado: (2020)

Role of p53 and CDKN2A Inactivation in Human Squamous Cell Carcinomas
por: Pacifico, Alessia, et al.
Publicado: (2007)

Antitumor mechanisms when pRb and p53 are genetically inactivated
por: Zhu, Liang, et al.
Publicado: (2014)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS
por: Stengel, Anna, et al.
Publicado: (2023)

Monosomal karyotype and chromosome 17p loss or TP53 mutations in decitabine-treated patients with acute myeloid leukemia
por: Becker, Heiko, et al.
Publicado: (2020)

DEVOLUTION—A method for phylogenetic reconstruction of aneuploid cancers based on multiregional genotyping data
por: Andersson, Natalie, et al.
Publicado: (2021)

Tracing the evolution of aneuploid cancers by multiregional sequencing with CRUST
por: Chattopadhyay, Subhayan, et al.
Publicado: (2021)

Somatic intronic TP53 c.375+5G mutations are a recurrent but under‐recognized mode of TP53 inactivation
por: Chui, M Herman, et al.
Publicado: (2021)

Biclonal plasma cell leukemia associated with a complex karyotype, TP53 deletion, and high‐risk disease
por: Xie, Wei, et al.
Publicado: (2020)

TP53 Abnormalities Are Underlying the Poor Outcome Associated with Chromothripsis in Chronic Lymphocytic Leukemia Patients with Complex Karyotype
por: Ramos-Campoy, Silvia, et al.
Publicado: (2022)

Assessment of clinical outcomes with immune checkpoint inhibitor therapy in melanoma patients with CDKN2A and TP53 pathogenic mutations
por: DeLeon, Thomas T., et al.
Publicado: (2020)

KRAS, TP53, CDKN2A, SMAD4, BRCA1, and BRCA2 Mutations in Pancreatic Cancer
por: Cicenas, Jonas, et al.
Publicado: (2017)

TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
por: Weinberg, Olga K., et al.
Publicado: (2022)

Heterogeneous side effects of cortical inactivation in behaving animals
por: Andrei, Ariana R, et al.
Publicado: (2021)

HER-2 activation and TP53 inactivation as predictors of survival in breast cancer
por: Andersen, TI, et al.
Publicado: (2000)

Coexistence of YWHAZ amplification predicts better prognosis in muscle-invasive bladder cancer with CDKN2A or TP53 loss
por: Liu, Shenghua, et al.
Publicado: (2016)

Differential profile of CDKN1A and TP53 expressions in bone marrow mesenchymal stromal cells from myeloid neoplasms
por: Lopes, Matheus Rodrigues, et al.
Publicado: (2016)

TP53 Mutations and CDKN2A Mutations/Deletions are Highly Recurrent Molecular Alterations in the Malignant Progression of Sinonasal Papillomas
por: Brown, Noah A., et al.
Publicado: (2020)

Side by side
por: Perlman, Itzhak, 1945-
Publicado: (1994)

Side by side
por: Molinsky, Steven J.
Publicado: (1989)

T antigen transformation reveals Tp53/RB-dependent route to PLAC1 transcription activation in primary fibroblasts
por: Chen, Y, et al.
Publicado: (2013)

Stepwise crosstalk between aberrant Nf1, Tp53 and Rb signalling pathways induces gliomagenesis in zebrafish
por: Luo, Juanjuan, et al.
Publicado: (2020)

Complete loss of TP53 and RB1 is associated with complex genome and low immune infiltrate in pleomorphic rhabdomyosarcoma
por: Beird, Hannah C., et al.
Publicado: (2023)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

CDKN2A gene inactivation in epithelial sporadic ovarian cancer
por: Niederacher, D, et al.
Publicado: (1999)

Side by side : activity workbook
por: Molinsky, Steven J.
Publicado: (1989)

Karyotypic complexity rather than chromosome 8 abnormalities aggravates the outcome of chronic lymphocytic leukemia patients with TP53 aberrations
por: Blanco, Gonzalo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_djro9hvo9oqlobcf7h33ft0gei